Ibrutinib, a first-generation BTK inhibitor that effectively inhibits B cell receptor and NFκB signal transduction [35,50], which may be beneficial to COVID-19 patients in pulmonary distress [51]. The gene discussed is BTK; the disease is COVID-19.